In Vitro Efficacy Testing Services
PKDERM excels in providing innovative and engaging in vitro solutions that utilize an extensive array of models to thoroughly assess the efficacy of your compound across the entire development process.
In Vitro Safety Testing Services
PKDERM experts are here to guide and support you throughout your product development journey, ensuring the safety of your product by helping you choose the most suitable in vitro tests.
Scientific Expertise and Training Services
PKDERM offers comprehensive consultancy support to guide and drive you throughout the development of your product. In addition, hands-on training can be organized on demand.
SERVICES
PKDERM is your trusted partner in animal-free in vitro testing.
We provide our partners in the cosmetic, dermatological, pharmaceutical, chemical, agrochemical and medical devices industries a full range of services based on animal-free in vitro methods, as well as consulting and training services throughout the development life cycle to ensure the safety and efficacy of new products.
Latest News & Events
Scientific Training on IVRT & IVPT in Lisbon
PKDERM was pleased to contribute to an advanced training course on In Vitro Release Testing (IVRT) and In Vitro Permeation Testing (IVPT) organized by Teledyne LABS at the Faculty of Pharmacy, University of Lisbon.
During this one-day event, Dr. Hanan Osman-Ponchet, Founder, CEO & CSO of PKDERM, delivered a theoretical and hands-on training session focused on IVPT methodologies using human skin. The course provided participants with practical insights into study design, execution, data interpretation, regulatory considerations, and best practices for topical and transdermal product evaluation.
This initiative reflects PKDERM’s commitment to knowledge sharing, scientific excellence, and the advancement of predictive in vitro methodologies for pharmaceutical, cosmetic, and dermatological applications.
Second European Patent Granted to PKDERM
PKDERM is proud to announce the grant of European Patent EP3922714 by the European Patent Office (EPO) for its innovation entitled:
“Use of a 3D Skin Model for Assessing Treatment of SARS-Coronavirus Skin Infection”
This achievement marks an important milestone in PKDERM’s innovation journey and highlights the company’s expertise in the development of advanced 3D human skin models. The patented technology provides a novel approach for studying SARS-coronavirus skin infections using human-relevant in vitro models, contributing to more predictive and translational biomedical research.
The patent reflects PKDERM’s ongoing commitment to scientific excellence, innovation, and the development of cutting-edge technologies that support research, drug discovery, and the advancement of alternative methods to animal testing.
PKDERM Co-Authors a Publication in Cell Reports Medicine
PKDERM is proud to have contributed to a new publication in Cell Reports Medicine, a leading journal in translational medicine. This collaborative research highlights an innovative therapeutic approach for the treatment of pulmonary fibrosis and demonstrates the value of advanced human-relevant models in drug development.
Using its proprietary human Precision-Cut Lung Slices (hPCLS) model, PKDERM contributed to the evaluation of EL244, a novel compound shown to prevent and attenuate fibrotic responses directly in human lung tissue. These results reinforce the importance of predictive human models for accelerating translational research and improving the development of new therapies.
This publication represents a significant achievement and reflects the strength of collaboration between academic and industrial partners working together to advance respiratory research and innovative treatment strategies.
PKDERM at in-cosmetics Global 2026 – Paris
PKDERM proudly participated in in-cosmetics Global 2026 in Paris, presenting its expertise in innovative in vitro skin models and safety and efficacy testing solutions. The event provided valuable opportunities to connect with clients, partners, and industry experts while exploring new collaborations in cosmetic science and innovation.
PKDERM at Cosmetotest 2026 – Lyon
PKDERM was delighted to participate in Cosmetotest 2026 in Lyon, a leading international symposium dedicated to preclinical and clinical testing for the cosmetics industry. The event provided an excellent opportunity to meet with scientists, industry experts, and innovation leaders, while showcasing PKDERM’s expertise in advanced in vitro skin models, dermal testing strategies, and safety and efficacy evaluation.
The symposium also offered valuable opportunities to discuss ongoing R&D projects, explore new collaborations, and share innovative approaches supporting the development of safer and more effective cosmetic products.
European-Funded Innovation Project for Advanced Lung Research
PKDERM is proud to lead an ambitious R&D project supported by the European Regional Development Fund (ERDF/FEDER) and the Région Sud Provence-Alpes-Côte d’Azur. Since 2024, our team has been developing an innovative dynamic air-liquid interface culture platform for human Precision-Cut Lung Slices (PCLS).
This next-generation model aims to provide a more physiologically relevant and predictive tool for studying pulmonary fibrosis and lung cancer, identifying novel biomarkers, evaluating innovative therapies, and supporting alternatives to animal testing.
Developed in collaboration with regional partners, including CHU Nice and IHU RespirERA, this project reflects PKDERM’s commitment to advancing respiratory research through innovative human-relevant models and cutting-edge technologies.
A Strong Start to 2026 at PKDERM
PKDERM began 2026 with several important milestones, reflecting the company’s continued commitment to scientific excellence and innovation.
The installation of a new QuantStudio™ 3 qPCR system has significantly strengthened PKDERM’s capabilities in transcriptomics and gene expression analysis, supporting increasingly advanced research projects.
At the same time, PKDERM successfully completed its first Precision-Cut Lung Slices (PCLS) experiments of the year, further expanding its expertise in human-relevant respiratory models and pulmonary fibrosis research.
The team also launched its first human skin cultures of 2026, supporting a new series of dermatology and advanced 3D skin model projects for efficacy and safety evaluation.
These achievements mark an exciting start to the year and reinforce PKDERM’s dedication to developing innovative in vitro models and cutting-edge solutions for the cosmetics, pharmaceutical, and biotechnology industries.
Happy New Year 2026!
Thank you to our clients, partners, and team for their trust and support. We look forward to another year of innovation, collaboration, and success together.
PKDERM Is Hiring a Laboratory Technician
PKDERM is expanding its team and is looking for a Laboratory Technician to join our innovative research environment in Sophia Antipolis.
This permanent position offers the opportunity to work on advanced cell culture techniques, 3D tissue models, and state-of-the-art in vitro assays supporting research and product development for the cosmetics, pharmaceutical, and biotechnology industries.
📍 Sophia Antipolis, France
📅 Start date: January 2026
📄 Permanent contract (CDI)
Join us and contribute to the development of innovative human-relevant in vitro models and testing solutions.
PKDERM at IFSCC 2025 – Cannes
PKDERM was delighted to participate in the IFSCC Congress 2025 in Cannes. During the event, PKDERM presented a scientific poster entitled “Implementation and Validation of a Pigmentation Model Using B16-F10 Melanoma Cells for Dermatological Applications”, highlighting our expertise in developing innovative in vitro models for skin research and cosmetic product evaluation.
The congress was also an opportunity to showcase PKDERM’s advanced safety and efficacy testing solutions and to discuss new collaborations supporting the future of cosmetic science.
PKDERM Expands to New Facilities
PKDERM is proud to announce its relocation to a new and larger facility in Sophia-Antipolis, marking an important milestone in the company’s growth journey. Designed to support innovation, collaboration, and scientific excellence, these new premises provide an enhanced environment for the development of advanced in vitro models and testing solutions.
This expansion reflects PKDERM’s continued commitment to investing in research and innovation, strengthening its capabilities, and supporting the growing needs of its clients in the cosmetics, pharmaceutical, and biotechnology sectors.
PKDERM at in-cosmetics Global 2025 – Amsterdam
PKDERM was delighted to participate in in-cosmetics Global 2025 in Amsterdam, one of the leading international events for the personal care industry. The exhibition provided an excellent opportunity to connect with cosmetic manufacturers, ingredient suppliers, and innovation leaders, while showcasing our advanced in vitro efficacy and safety testing solutions for cosmetic product development.
PKDERM and GENXMAP Join Forces to Advance Cosmetic Innovation Through RNA-Seq Technology
Antibes, May 12, 2025 – PKDERM, a leading provider of innovative in vitro models and testing solutions for the cosmetics industry, and GENXMAP, a pioneer in advanced genomics solutions and RNA sequencing (RNA-Seq) analysis, are pleased to announce a strategic partnership.
This collaboration aims to integrate the molecular insights generated by RNA-Seq into PKDERM’s in vitro testing platforms, providing cosmetic companies with powerful new tools to support product innovation, efficacy evaluation, and scientific validation. By combining PKDERM’s expertise in predictive human-relevant models with GENXMAP’s cutting-edge transcriptomic technologies, the partnership will enable a deeper understanding of cellular responses and mechanisms of action.
Together, PKDERM and GENXMAP are committed to delivering advanced, data-driven solutions that help accelerate cosmetic research and development while supporting scientifically robust product claims.
Read the full press release: PKDERM – GENXMAP Press Release.
PKDERM Joins the France 2030 Export Program
PKDERM is proud to have been selected to join the France 2030 Export Program, an initiative designed to support innovative French companies in their international development. As a France 2030 laureate, PKDERM will benefit from dedicated support to accelerate its global growth and expand the reach of its innovative in vitro testing solutions.
This recognition reflects PKDERM’s commitment to scientific excellence, innovation, and the development of advanced human-relevant models for the cosmetics, pharmaceutical, and biotechnology industries. Through the support of Team France Export and Business France, PKDERM looks forward to strengthening its international presence and building new collaborations worldwide.
PKDERM Supports Ethical Research and Innovation
PKDERM was honored to contribute to the Prix Descroix-Vernier EthicScience 2025 as a member of the Strategic Committee. This prestigious initiative recognizes innovative scientific projects that advance alternatives to animal testing and promote ethical biomedical research.
Through its involvement, PKDERM reaffirms its commitment to developing human-relevant in vitro models and supporting scientific innovation that combines excellence, sustainability, and animal welfare.
PKDERM Joins Cosmetic Valley
PKDERM is proud to have joined Cosmetic Valley, the leading French competitiveness cluster dedicated to the cosmetics and fragrance industry. This membership marks an important milestone in PKDERM’s development and reinforces our commitment to innovation, scientific excellence, and collaboration within the cosmetics ecosystem.
As a specialist in in vitro safety and efficacy testing, PKDERM develops advanced skin models and innovative testing solutions to support cosmetic product development. Joining Cosmetic Valley provides new opportunities to collaborate with industry leaders, research organizations, and innovative companies, while contributing to the future of cosmetic science and sustainable innovation.
PKDERM at CPLF 2025 – Marseille
PKDERM was pleased to participate in the 29th Congrès de Pneumologie en Langue Française (CPLF) in Marseille. The congress provided an excellent opportunity to engage with experts in respiratory research and innovation while showcasing our human Precision-Cut Lung Slices (PCLS) model, a physiologically relevant platform for studying lung diseases and evaluating innovative therapeutic approaches.
PKDERM at Cosmet’Agora 2025
PKDERM proudly participated in Cosmet’Agora 2025 in Paris, presenting its expertise in advanced in vitro testing and innovative skin models. The event offered valuable opportunities to connect with cosmetic industry professionals and discuss new approaches for safety and efficacy evaluation.
Happy New Year 2025!
Thank you to our clients, partners, and team for their trust and support. We look forward to another year of innovation, collaboration, and success together.
PKDERM Receives Its First European Patent
PKDERM is proud to announce the grant of its first European patent for the In Vitro Airways Nebulization Assay, a significant milestone in the company’s innovation journey.
This patented technology reflects PKDERM’s commitment to developing advanced and physiologically relevant in vitro models that support respiratory research, drug development, and the evaluation of inhaled products. The patent recognizes years of scientific research, technological development, and dedication to creating innovative solutions for the life sciences industry.
This achievement further strengthens PKDERM’s position as a leader in human-relevant testing approaches and highlights the company’s ongoing investment in research, innovation, and intellectual property.
International Recognition for Innovation and Excellence
In 2024, PKDERM received two major awards from the GHP Biotechnology Awards, recognizing the company’s expertise and continued commitment to innovation:
- Best In-Vitro Safety & Efficacy Testing Specialists 2024 – France
- GHP Innovation Excellence Award 2024
These distinctions reflect PKDERM’s dedication to advancing predictive in vitro testing, skin research, and the development of advanced human tissue models that support safety and efficacy testing for the cosmetics, dermatology, pharmaceutical, and biotechnology industries.
Through innovative skin and lung models, alternative testing methods and scientifically robust solutions, PKDERM helps accelerate product development while delivering reliable data for cosmetic testing, dermatological research, respiratory research, pharmaceutical development, and biotechnology applications.
We are honored by this recognition and grateful to our clients, partners, and team members whose trust and collaboration make these achievements possible.
PKDERM at LIVe 2024
PKDERM was proud to participate in LIVe 2024, a leading event dedicated to advancements in in vitro lung research. As an event sponsor, PKDERM had the opportunity to engage with experts and industry partners while showcasing its latest developments in pulmonary research. Through scientific presentations and posters, PKDERM highlighted its expertise in advanced lung models, including innovative approaches for studying lung fibrosis and respiratory diseases.
PKDERM at ESTIV 2024 – Prague
PKDERM was pleased to participate in ESTIV 2024, the annual conference of the European Society of Toxicology In Vitro, held in Prague. The event provided an excellent opportunity to share our latest research and connect with experts in in vitro toxicology and alternative testing methods. Through oral and poster presentations, PKDERM showcased its expertise in advanced human-relevant models, including innovative applications in pulmonary fibrosis research and wound healing studies.
𝐎𝐫𝐚𝐥 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:Successful development of 3D human precision-cut lung slices (PCLS) for modeling pulmonary fibrosis. This exciting project was a collaboration between PKDERM and OTR3. (Session ESR2, O-ESR2-4, 5:30 PM – 7:30 PM)
𝐏𝐨𝐬𝐭𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: Effect of topical probiotic formulations on wound healing in dog keratinocytes. This project was a collaboration between PKDERM and Probiotic Group. (P11)
PKDERM at Cosmetotest 2024
PKDERM proudly participated in Cosmetotest 2024 in Lyon, presenting its expertise in advanced in vitro skin models. Through scientific exchanges and a conference presentation, PKDERM highlighted innovative approaches using 2D and 3D skin models to study skin inflammation and support cosmetic product development.
Webinar on Precision-Cut Lung Slices (PCLS) for Pulmonary Fibrosis Research
PKDERM was pleased to contribute to a webinar organized by Edelweiss Connect on the topic of advances in in vitro modeling of pulmonary fibrosis. During this session, Hanan Osman-Ponchet, Founder, CEO & CSO of PKDERM, presented the latest developments in Precision-Cut Lung Slices (PCLS) technology and its applications as a physiologically relevant model for studying lung diseases and evaluating innovative therapeutic approaches.
PKDERM at in-cosmetics Global 2024 – Paris
PKDERM was pleased to participate in in-cosmetics Global 2024 in Paris, one of the leading international events for the cosmetics and personal care industry. The exhibition provided an excellent opportunity to connect with customers, partners, and industry experts, while showcasing our innovative in vitro efficacy and safety testing solutions. We were delighted to exchange ideas, explore new opportunities, and strengthen collaborations within the global cosmetics community.
PKDERM Publication Recognized Among IJMS Top Viewed Papers 2023
PKDERM is proud to announce that its publication, “Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?”, was recognized among the Top Viewed Papers of the International Journal of Molecular Sciences (IJMS) in 2023, highlighting the impact and visibility of our research in skin biology and infectious diseases.
📖 Read the full paper here.
PKDERM at Cosmet’Agora 2024
PKDERM proudly participated in Cosmet’Agora 2024 in Paris, presenting its expertise in advanced in vitro testing and innovative skin models. The event offered valuable opportunities to connect with cosmetic industry professionals and discuss new approaches for safety and efficacy evaluation.
A Milestone in PKDERM’s Research Journey
PKDERM was delighted to celebrate the PhD graduation of Manon Barthe from Université Côte d’Azur. As the first doctoral project completed within our laboratory, this achievement reflects PKDERM’s ongoing investment in research, innovation, and scientific training.
The thesis explored the potential role of the skin as an alternative route of SARS-CoV-2 infection and contributed to advancing knowledge in skin biology and viral entry mechanisms. Through collaborative research and academic partnerships, PKDERM continues to support the development of innovative in vitro models and cutting-edge scientific discoveries.
Happy New Year 2024!
Thank you to our clients, partners, and team for their trust and support. We look forward to another year of innovation, collaboration, and success together.
Dr. Hanan Osman-Ponchet Named Dermatology Solutions CEO of the Year 2023 (France)
PKDERM is delighted to celebrate the recognition of its Founder, CEO & CSO, Dr. Hanan Osman-Ponchet, who received the Dermatology Solutions CEO of the Year 2023 (France) award at the Global CEO Excellence Awards. This distinction recognizes her dedication to scientific innovation, business leadership, and the development of advanced in vitro models supporting research and product development in the life sciences sector.
Webinar on In Vitro Modeling of Lung Diseases Using hPCLS
PKDERM was pleased to contribute to a webinar organized by Precisionary on the topic of in vitro modeling of lung diseases using human Precision-Cut Lung Slices (hPCLS). During the session, Dr. Hanan Osman-Ponchet, Founder, CEO & CSO of PKDERM, presented the successful preparation of hPCLS from human surgical lung resections using the Compresstome® VF-300-0Z vibrating microtome, as well as the development of a pulmonary fibrosis model through the induction of fibrotic responses using a profibrotic cocktail. The webinar highlighted the value of hPCLS as a physiologically relevant platform for respiratory research, disease modeling, and preclinical drug evaluation.
PKDERM Recognized as Most Innovative Dermatology Solutions Firm in France 2023
PKDERM was honored to receive the Most Innovative Dermatology Solutions Firm in France 2023 award from Global Health & Pharma (GHP) during the International Life Sciences Awards. This recognition reflects our dedication to advancing skin research through innovative in vitro models, cutting-edge technologies, and scientifically robust solutions for safety and efficacy evaluation.
Find all services in our commercial flyer